AstraZeneca (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (24)

2023

  1. Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD

    Respiratory Research, Vol. 24, Núm. 1

  2. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2803-2811

  3. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

    The Lancet Child and Adolescent Health, Vol. 7, Núm. 3, pp. 180-189

  4. Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

    Journal of the Pediatric Infectious Diseases Society, Vol. 12, Núm. 8, pp. 477-480

  5. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1759-1770.e7

  6. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer

    Future oncology (London, England), Vol. 19, Núm. 35, pp. 2349-2359

2022

  1. Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

    Clinical Cancer Research, Vol. 28, Núm. 20, pp. 4536-4550

  2. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

    New England Journal of Medicine

  3. The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study

    Respiratory Medicine, Vol. 200

  4. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 12, pp. 1142-1154

  5. Treatable traits in the NOVELTY study

    Respirology, Vol. 27, Núm. 11, pp. 929-940

2021

  1. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study

    npj Breast Cancer, Vol. 7, Núm. 1

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial

    Journal of Clinical Oncology

  2. Combined MEK and PI3K/p110β inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features

    Cancer Research, Vol. 80, Núm. 4, pp. 843-856

  3. Reimagining global oncology clinical trials for the postpandemic era: A call to arms

    JCO Global Oncology, pp. 1357-1362

2019

  1. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial

    JAMA Oncology, Vol. 5, Núm. 11, pp. 1556-1563

  2. Meta-Analysis Design and Results in Real Life: Problem Solvers or Detour to Maze. A Critical Review of Meta-Analysis of DAPT Randomized Controlled Trials

    Cardiovascular Revascularization Medicine, Vol. 20, Núm. 10, pp. 897-906

2018

  1. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  2. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210